Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIL-7-hyFc for Lymphopenic Glioma
NCT03687957Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2019
- Primary completion
- Feb 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efineptakin alfa in glioma (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 30 days, Dose-limiting Toxicities at 30 days and 2 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
efineptakin alfa
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03687957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687957.